Amylyx Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q3 2022 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Amylyx Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2022 to Q2 2024.
  • Amylyx Pharmaceuticals, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 20.6 %, a 19.6% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 20.6 +3.37 +19.6% Jun 30, 2024
Q1 2024 18.7 +1.63 +9.54% Mar 31, 2024
Q4 2023 16 -0.78 -4.65% Dec 31, 2023
Q3 2023 14.8 -13.5 -47.7% Sep 30, 2023
Q2 2023 17.2 Jun 30, 2023
Q1 2023 17.1 Mar 31, 2023
Q4 2022 16.8 Dec 31, 2022
Q3 2022 28.3 Sep 30, 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.